Reach Us +44-1753390542
Comparing Outcomes for Rare Primary Hepatic Tumors after Liver Transplantation | OMICS International | Abstract
ISSN: 2161-0991

Journal of Transplantation Technologies & Research
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Comparing Outcomes for Rare Primary Hepatic Tumors after Liver Transplantation

Nhu Thao T Nguyen1*, Theresa R Harring1, Jacfranz J Guiteau1, Ron T Cotton1, Ismael Salas de Armas1, Hao Liu2, John A Goss1 and Christine A O’Mahony1
1Division of Abdominal Transplantation and Hepatobiliary Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, 1709 Dryden Road Suite 1500, Houston, Texas 77030
2Division of Biostatistics, Dan L. Duncan Cancer Center, Department of Medicine, Section of Hematology/Oncology, Baylor College of Medicine, One Baylor Plaza, 450A, Houston, Texas 77030
Corresponding Author : Nhu Thao T. Nguyen
Michael E. DeBakey Department of Surgery
1709 Dryden, Ste 1537
Houston, TX 77030
Tel: 713.798.7949
Fax: 713.798.8319
E-mail: [email protected]
Received November 01, 2011; Accepted December 09, 2011; Published December 13, 2011
Citation: Nguyen NTT, Harring TR, Guiteau JJ, Cotton RT, de Armas IS, et al. (2011) Comparing Outcomes for Rare Primary Hepatic Tumors after Liver Transplantation. J Transplant Technol Res 1:106. doi:10.4172/2161-0991.1000106
Copyright: © 2011 Nguyen NTT, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Aim: Liver transplantations (LT) have proven to be a successful treatment for many tumors of the liver. The goal of this study was to evaluate the outcomes of liver transplantations in patients with primary liver tumors with a focus on rarer malignancies. Methods: The UNOS database catalogues all adult patients who underwent LT for a primary liver tumor from 1992-2008. Of the 73, 231 liver transplantations, 5,682 patients with liver tumors were identified and categorized by indication for LT: hepatocellular carcinoma (HCC, n=5272), hepatic epithelioid hemangioendothelioma (HEH, n=85), cholangiocarcinoma (n=249), sarcomas (n= 11) and combined HCC-Cholangiocarcinomas (HCC-CC, n=12). Survivals were calculated using Kaplan-Meier and log rank tests. Results: 5,629 patients received LT for solid liver tumors. HCC patients and their allografts survived longer than those transplanted for cholangiocarcinomas (p=0.001, 0.002) or for HCC-CC (p=0.025, 0.004). Overall survival rates of HCC patients were 86.4%, 71.3%, and 61.2% at 1, 3 and 5 years, respectively. Cholangiocarcinoma patients had survival rates of 79.7%, 60.3% and 45.5% at 1-, 3- and 5-years from transplant. HCC-CC patients had the worst overall survival of 72.9%, 39.1% and 39.1% at 1, 3 and 5 years. Allograft survival in HCC-CC patients was comparatively low, averaging 65.6%, 35.2% and 0% at 1-, 3- and 5-years. HEH patients and their allografts survived the longest with overall survival of 83.9%, 77.8% and 73.5% at 1, 3 and 5 years, respectively, and allograft survival at 76.8%, 69.8% and 64.3%. Conclusion: Our data reveals overall survival was significantly better in HEH patients when compared to HCC, cholangiocarcinoma and HCC-CC patients after LT. In fact, HCC-CC patients fared the worst, both in patient and allograft survival, as compared to HCC and HEH. Results of cholangiocarcinoma patients show worse survival after LT compared to HCC and HEH, though recent evidence suggests adjuvant therapy will change outcomes for the future. Our findings suggest transplantation for HCC-CC may not be sufficient treatment. Other forms of adjuvant and neoadjuvant therapy may be indicated, warranting further research.


Recommended Conferences

4th Annual Summit on Surgery and Transplantation

Singapore, Singapore

International Congress on Gastroenterology and Liver Transplant

Auckland, New Zealand
Share This Page